


EG30 for the treatment of Alzheimer's disease (Ramot)**code:** 10-2011-274[Ehud GAZIT](#), T.A.U Tel Aviv University, Life Sciences, School of Molecular Cell Biology & Biotechnology

EG-30: clinical phase drug for AMD and Glaucoma

EG-30 - the highlights:

- ◆ Excellent safety profile in healthy volunteers and glaucoma patients
 - Low systemic exposure
 - No increase in IOP in glaucoma patients treated with EG-30 for 16days (eye drops)
- ◆ Extensive safety and efficacy preclinical package:
 - EG-30 inhibit the formation of amyloid beta oligomers and serve as a cytoprotectant agent
 - Efficacy in dry AMD and glaucoma animal models
 - Safety and toxicology including 6 months toxicology studies in rabbits and monkeys
- ◆ An FDA approved development path allowing a single confirmatory study for FDA approval of EG-30 for both glaucoma and dry AMD
- ◆ New derivatives for Alzheimer treatment

Contact for more information:Tali Aloya , BD Life Sciences, +972-3-7684939

Ramot at Tel Aviv University Ltd. P.O. Box 39296, Tel Aviv 61392 ISRAEL

Phone: +972-3-6406608

Fax: +972-3-6406675